ZA868516B - Method for preparing antihemophilic factor(ahf)by cold precipitation and for improving solubility of recovered ahf product - Google Patents

Method for preparing antihemophilic factor(ahf)by cold precipitation and for improving solubility of recovered ahf product

Info

Publication number
ZA868516B
ZA868516B ZA868516A ZA868516A ZA868516B ZA 868516 B ZA868516 B ZA 868516B ZA 868516 A ZA868516 A ZA 868516A ZA 868516 A ZA868516 A ZA 868516A ZA 868516 B ZA868516 B ZA 868516B
Authority
ZA
South Africa
Prior art keywords
ahf
cold precipitation
fibrinogen
product
fibronectin
Prior art date
Application number
ZA868516A
Other languages
English (en)
Inventor
Maria Erlinda C Sarno
Clifford R Graf
Rodolfo A Vasquez
Original Assignee
Baxter Travenol Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25168481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA868516(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Travenol Lab filed Critical Baxter Travenol Lab
Publication of ZA868516B publication Critical patent/ZA868516B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
ZA868516A 1985-11-08 1986-11-10 Method for preparing antihemophilic factor(ahf)by cold precipitation and for improving solubility of recovered ahf product ZA868516B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79655985A 1985-11-08 1985-11-08

Publications (1)

Publication Number Publication Date
ZA868516B true ZA868516B (en) 1987-08-26

Family

ID=25168481

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868516A ZA868516B (en) 1985-11-08 1986-11-10 Method for preparing antihemophilic factor(ahf)by cold precipitation and for improving solubility of recovered ahf product

Country Status (9)

Country Link
US (1) US4739039A (xx)
EP (1) EP0221566B1 (xx)
JP (1) JPH0822879B2 (xx)
AT (1) ATE79266T1 (xx)
AU (1) AU6487286A (xx)
CA (1) CA1293941C (xx)
DE (1) DE3686390T2 (xx)
ES (1) ES2051686T3 (xx)
ZA (1) ZA868516B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
DE3806562A1 (de) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
EP0399321B1 (en) * 1989-05-24 1993-06-23 Miles Inc. Gel filtration of heat treated factor viii
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
US5259971A (en) * 1992-03-02 1993-11-09 Cryolife, Inc. Method of preparing fibrinogen
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
US5523893A (en) * 1994-08-24 1996-06-04 Northrop Grumman Corporation Strain free temperature-compensated optical mounts
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
EP3057987B1 (en) 2013-10-18 2020-12-23 Novasep Process Purification of proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE713764A (xx) * 1967-05-01 1968-09-16 Baxter Travenol Lab
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
GB1507198A (en) * 1974-04-12 1978-04-12 Squibb & Sons Inc Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
CA1054052A (en) * 1976-08-14 1979-05-08 Edward Shanbrom Simplified method for preparation of high yield, high purity factor viii concentrate
US4104266A (en) * 1977-04-14 1978-08-01 American National Red Cross Method for preparation of antihemophilic factor
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
US4294826A (en) * 1980-05-07 1981-10-13 Armour Pharmaceutical Company Process for the preparation of highly purified antihemophilic factor
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4406886A (en) * 1983-01-14 1983-09-27 University Patents, Inc. Purification of antihemophilia factor VIII by precipitation with zinc ions
DE3318521A1 (de) * 1983-05-20 1984-11-22 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate

Also Published As

Publication number Publication date
EP0221566A3 (en) 1987-10-07
ATE79266T1 (de) 1992-08-15
JPH0822879B2 (ja) 1996-03-06
EP0221566B1 (en) 1992-08-12
CA1293941C (en) 1992-01-07
DE3686390D1 (de) 1992-09-17
DE3686390T2 (de) 1993-03-04
EP0221566A2 (en) 1987-05-13
ES2051686T3 (es) 1994-07-01
JPS62181220A (ja) 1987-08-08
AU6487286A (en) 1987-05-14
US4739039A (en) 1988-04-19

Similar Documents

Publication Publication Date Title
EP0221566A3 (en) Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product
ATE305011T1 (de) Verfahren zur herstellung von virusfreien thrombin zur bereitung von fibrinkleber aus menschlichem plasma-pool
IL122665A (en) Method and apparatus for inactivating contaminants in blood products
DE69002427D1 (de) Verfahren zur herstellung eines konzentrats des faktor viii-von willebrand-faktor-komplexes der blutgerinnung aus vollplasma.
EP0125520A3 (en) A process and a plant for the recovery of one or more constituents from a gas mixture
EP0022052A3 (en) Process for the separation and isolation of the ahf fraction, the fibronectin fraction and the von willebrand's ristocetin cofactor fraction from blood plasma
GR3026053T3 (en) Recovery of citric acid from impure process streams by addition of strong acids and salts thereof.
US4404131A (en) Method of producing a factor-VIII(AHF)-high-concentrate
EP0399573A3 (en) Process for recovery of amino acid from aqueous mixtures
DE69311337D1 (de) Verfahren zur Reinigung von Proteinen
KR880000465A (ko) 순수한 알부민의 제조방법
EP0304024A3 (en) Agarose purification method using glycol
FI915813A0 (fi) Menetelmä luonnollisesti tuotetun kymosiinin talteenottamiseksi
FR2632302B1 (fr) Procede de recuperation d'acide citrique a partir d'une liqueur en contenant
GR3007446T3 (xx)
HUT61053A (en) Process for obtaining recombinant proteins
EP0237981A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII enthaltenden, sterilen Präparates
ATE35533T1 (de) Verfahren zur rueckgewinnung von reiner benzoesaeure.
ATE214625T1 (de) Verfahren zur wiedergewinnung von zitronensäure
TW254947B (en) An improved process for hemoglobin purification
MX9701265A (es) Procedimiento para tratar una corriente acuosa de desechos de fluoruro de potasio y para convertir este fluoruro de potasio en fluoruro de hidrogeno e hidroxido de potasio.
DE69210816D1 (de) Verfahren zur Entfernung von abgelagerten Verunreinigungen in einem organischen Strom zur Erzeugung reiner Phosphorsäure
ES8500059A1 (es) Procedimiento para la produccion de concentrado de factor antihemofilico.